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Acute exposure to silica nanoparticles aggravate airway
inﬂammation: different effects according to surface
characteristics
Hye Jung Park1, Jung-Ho Sohn1,2, Yoon-Ju Kim1, Yoon Hee Park1, Heejae Han1, Kyung Hee Park1,
Kangtaek Lee3, Hoon Choi3, Kiju Um3, In-Hong Choi4, Jung-Won Park1 and Jae-Hyun Lee1
Silica nanoparticles (SNPs) are widely used in many scientiﬁc and industrial ﬁelds despite the lack of proper evaluation of their
potential toxicity. This study examined the effects of acute exposure to SNPs, either alone or in conjunction with ovalbumin
(OVA), by studying the respiratory systems in exposed mouse models. Three types of SNPs were used: spherical SNPs (S-SNPs),
mesoporous SNPs (M-SNPs), and PEGylated SNPs (P-SNPs). In the acute SNP exposure model performed, 6-week-old BALB/c
female mice were intranasally inoculated with SNPs for 3 consecutive days. In the OVA/SNPs asthma model, the mice were
sensitized two times via the peritoneal route with OVA. Additionally, the mice endured OVA with or without SNP challenges
intranasally. Acute SNP exposure induced signiﬁcant airway inﬂammation and airway hyper-responsiveness, particularly in the
S-SNP group. In OVA/SNPs asthma models, OVA with SNP-treated group showed signiﬁcant airway inﬂammation, more than
those treated with only OVA and without SNPs. In these models, the P-SNP group induced lower levels of inﬂammation on
airways than both the S-SNP or M-SNP groups. Interleukin (IL)-5, IL-13, IL-1β and interferon-γ levels correlated with airway
inﬂammation in the tested models, without statistical signiﬁcance. In the mouse models studied, increased airway inﬂammation
was associated with acute SNPs exposure, whether exposed solely to SNPs or SNPs in conjunction with OVA. P-SNPs appear to
be relatively safer for clinical use than S-SNPs and M-SNPs, as determined by lower observed toxicity and airway system
inﬂammation.
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INTRODUCTION
Nanotechnology is a recently developing ﬁeld that allows for
the production of nanoparticles (NPs) at supramolecular
levels, typically o100 nm. Nanotechnology has been applied
to many industrial ﬁelds, including textiles, cosmetics, food
packaging and medicines. In particular, the application of
nanotechnology in the medical ﬁeld has improved various
biotechnological processes such as drug synthesis and their
targeted delivery. Nanotechnology is expected to progress and
expand in the future.1–4 The increasing applications of nano-
technology warrant an increased study of the toxicity of NPs,
with emphasis on their potential safety issues. Studies thus far
have revealed that NPs can alter immune function and cause
inﬂammation in various organs and systems. The toxicity of
NPs, particularly associated with the liver, kidney, lung and
immune system, has been clearly established.5–10 These toxicity
studies and their results have been helpful for determining the
concentration, size and surface pattern of NPs that should be
selected for safe application.
Of the various clinical routes of NP administration,
inhalation is the main route of exposure due to the small
size of NPs and their ease of airborne dispersion. Humans
can be easily exposed to NPs unintentionally via aerosolization.
Recent clinical studies have shown that occupational exposure
during the manufacturing of NPs can cause respiratory
diseases such as asthma and bronchitis.11–13 Therefore, airway
toxicity related to NPs has garnered considerable recent
attention. Asthma, a chronic inﬂammatory airway disease
characterized by variable bronchial obstruction, is a common,
highly prevalent and signiﬁcant airway disease. There are
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many risk factors for developing or aggravating asthma
and asthma-like airway diseases such as air pollutants,
cigarette smoking and viral infection.14–16 These factors, as
well as ﬁne materials like NPs, may induce and aggravate
asthma. Many studies seeking to understand and reduce the
toxicity associated with NPs, have sought to examine them
in more detail, as well as their characteristics, such as surface
charge and surface pattern, which contribute to airway
inﬂammation.17–19
Silica, or silicon oxide (SiO2), is naturally found as sand or
quartz. Silica is a main component of glass and concrete.
Owing to its optical, thermodynamic characteristics and
chemical durability, silica has been used as a heat-resistant
glass and semiconductor; it is commonly used in optical
communications systems and ceramic technology. However,
silica is a well-known cause of pneumoconiosis, often present-
ing as chronic bronchitis, emphysema and lung ﬁbrosis.20,21
In addition, lung cancer has been associated with silicosis,
which is induced by inhalation of silica.22 Silicosis may
cause various autoimmune disorders, including rheumatoid
arthritis, systemic lupus erythematosus, systemic sclerosis and
vasculitis.23,24 Due to these potential health risks, the use of
silica should be carefully regulated and handled with proper
safety precautions.
Silica NPs (SNPs) have recently been used in biosciences,
medicines and daily life, after studies have revealed that SNPs
are relatively safe.25–28 Unfortunately, some studies have since
revealed inhalant-associated toxicity of SNPs in chronic expo-
sure conditions;29,30 however, the acute effects of SNPs on
airway systems has not yet been fully evaluated in vivo.
Especially, aggravating effects of SNPs on airway systems in
asthma mice model induced by ovalbumin (OVA) sensitization
and challenges has not been well known. Moreover, there are
few studies examining a counterplan for reducing toxicity
related to SNPs. In this study, exposure to SNPs alone as well
as in conjunction with OVA was induced to determine the
toxicity of these NPs on airway systems and examine any
associated aggravation of airway inﬂammation. Furthermore,
various surface patterns were studied to determine a possible,
relatively safe SNP with reduced toxicity.
MATERIALS AND METHODS
Preparation and characterization of SNPs
This study examined three types of SNPs: spherical (S-SNPs),
mesoporous (M-SNPs) and PEGylated (P-SNPs; PEG, polyethylene
glycol). To prepare the S-SNPs, 11.87ml of ethanol (Sigma-Aldrich,
St. Louis, MO, USA), 2.1 ml of distilled (DI) water, 0.67ml of
tetraethoxysilane (Sigma-Aldrich) and 0.36ml of 5 M NH4OH
(Sigma-Aldrich) were mixed in a vial and stirred for 24 h.
M-SNPs were synthesized using 53.4 g of DI water, 6.24 g of
cetyltrimethylammonium chloride (Sigma-Aldrich) and 0.3 g of
sodium acetate (Sigma-Aldrich), were mixed well, and then heated
in a 65 °C oil bath. After heating for 1 h, 3.9 ml of tetraethoxysilane
was slowly added to the mixture and then stirred for 24 h.
The resulting suspensions were puriﬁed by centrifugation,
re-dispersed in ethanol and DI water, and then ﬁnally re-dispersed
in DI water.
P-SNPs were prepared by surface functionalization of S-SNP.
Brieﬂy, thiol-functionalized S-SNP was prepared by adding
(3-mercaptopropyl) trimethoxysilane (10% of tetraethoxysilane) 5 h
after the addition of NH4OH during synthesis of S-SNP. After
puriﬁcation, these particles were conjugated with maleimide-
functionalized PEG (molecular weight: 2000) in DI water for 24 h
(weight ratio: ~ 0.5:1). Excess amount of PEG was removed by
centrifugation and dispersed in DI water to obtain P-SNP.
Visualization and surface area calculation of SNPs
To characterize the SNPs, transmission electron microscopy was
performed using a Tecnai 20 (FEI Co., Hillsboro, OR, USA). The
SNPs were diluted to a concentration of 1 mgml− 1 in a phosphate-
buffered saline solution. Transmission electron microscopy specimens
of the diluted SNPs were prepared by placing one drop on a carbon-
coated copper grid, which was allowed to dry at 60 °C for 15min.
Transmission electron microscopy analyses were performed at 25± 2 °
C; each SNP measured ~ 100 nm (Figure 1). These analyses indicated
that S-SNPs and M-SNPs had spherical and mesoporous morpholo-
gies, respectively. The P-SNPs also demonstrated spherical
morphology.
Nitrogen sorption experiments were performed at 77 K with the
Micromeritics ASAP 2020 system (Micromeritics, Norcross, GA,
USA). Speciﬁc surface area and pore size of the particles were
calculated using the Brunauer-Emmett-Teller equation and the
Barrett-Joyner-Halenda method, based on the desorption branch,
respectively.
Figure 1 Transmission electron microscopy images of (a) S-SNPs, (b) M-SNPs and (c) P-SNPs. M-SNP, mesoporous silica nanoparticle;
P-SNP, PEGylated silica nanoparticle; S-SNP, spherical silica nanoparticle.
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Animals
Female BALB/c mice, between 5 and 6 weeks old, were used in this
study (Orient, Daegeon, Korea). All mice were maintained at
conventional animal facilities under speciﬁc, pathogen-free conditions
(room temperature of 21–24 °C, relative humidity between 45% and
70%, with a 12-h light/dark cycle). All experimental protocols were
approved by the Animal Research Ethics Board of Yonsei University
(Seoul, Korea).
Direct acute exposure to SNPs
To establish the effects of SNPs in the airway system, the mice were
intranasally inoculated with SNPs (S-SNPs, M-SNPs and P-SNPs in
S-SNP group, M-SNP group and P-SNP group, respectively) or saline
on days 0, 1, and 2 (Figure 2a). All mice were killed 48 h after the last
intranasal inoculation.
Establishment of OVA-induced acute asthma model with
SNP exposure (OVA/SNPs asthma model)
To make acute asthma mice model, mice were sensitized with an
intraperitoneal injection of either 200 μl of 10 μg OVA (Sigma-
Aldrich) suspended in 1% aluminum hydroxide (Resorptar, Indergen,
NY, USA) or 200 μl of saline on days 1 and 14. On days 21, 22 and 23,
the OVA-sensitized mice were challenged intranasally with 30 μl of
OVA (1mgml− 1) in saline solution. SNPs (S-SNPs, M-SNPs and
P-SNPs in S-SNP group, M-SNP group and P-SNP group, respec-
tively) or saline were co-administered by intranasal inoculation of
200 μg (Figure 2b). All mice were killed 48 h after the last intranasal
inoculation.
Measurement of airway hyper-responsiveness
Airway hyper-responsiveness (AHR) in response to inhaled aerosolized
methacholine was measured using a forced oscillation technique
(FlexiVent; SCIREQ, Montreal, QC, Canada) 48 h after the last
intranasal inoculation. Cannulas were inserted into anesthetized mice
via tracheostomy, after which the mice were connected to a ventilator.
Aerosolized phosphate-buffered saline or methacholine at varying
concentrations, 3.125, 6.25, 12.5, 25.0 and 50.0mgml− 1, was diffused
to the mice for 10 s via a nebulizer. AHR was measured and
continuously recorded for up to 2min.
Bronchoalveolar lavage and inﬂammatory cell counting
To collect bronchoalveolar lavage ﬂuid (BALF), lung lavage was
performed three times by passing 1ml of Hank’s Balanced Salt
Solution through the tracheal tube. The recovered BALF was
centrifuged at 4 °C for 3min at 1500 g. The cellular pellet was
resuspended in 300 μl Hank’s Balanced Salt Solution. One part of
the resuspended BALF cells (250 μl) were centrifuged by cytocentri-
fugation (Cytospin 3; Thermo, Waltham, MA, USA) at 4 °C for 5min
at 1000 r.p.m. and were pelleted to cytospin slides. The slides were
stained with hematoxylin and eosin (Hemacolor, Merck, Darmstadt,
Germany) and counted the differential inﬂammatory cells including
neutrophils, eosinophils, lymphocytes and macrophages (200 cells per
cytospin). The remaining resuspended BALF cells (50 μl) were used for
counting the total number of cells using a hemocytometer and trypan
blue staining.
Measurement of cytokine levels
Concentrations of interleukin (IL)-5, IL-13, IL-1β and interferon-γ in
the lung tissues were assessed by ELISA (R&D Systems, San Diego,
CA, USA) according to the manufacturer’s instructions. The ELISA
detection ranges for IL-5, IL-13, IL-1β and interferon-γ are 31.3–2000,
62.5–4000, 15.6–1000 and 31.3–2000 pgml− 1, respectively.
Histological analysis
After the use of one lung in the collection of BALF, the other lung was
ﬁxed in 4% formalin and embedded in parafﬁn. Lung sections were
cut into 3- to 4-μm thick segments and stained with hematoxylin and
eosin and periodic acid-Schiff for histological analysis. The slides were
observed under light microscope.
Statistical analysis
All results are expressed as the mean± s.e.. One-way analysis of
variance was performed using SPSS statistical software version 12.0
(SPSS Inc., Chicago, IL, USA). The AHR data were analyzed with
repeated analysis of variance measures, followed by a post hoc
Bonferroni test. The remaining data were analyzed with one-way
analysis of variance followed by a post hoc Bonferroni test. P-values
o0.05 were considered statistically signiﬁcant.
RESULTS
Difference and chemical characteristics of three kinds of
SNPs
The surface area calculated using the Brunauer-Emmett-Teller
equation of S-SNPs and M-SNPs was 12.7 and 70.6m2 g− 1,
respectively. The surface area of P-SNPs was similar to those of
S-SNPs. The average pore diameter of the M-SNPs was
calculated to be 3.0 nm using the Barrett-Joyner-Halenda
method.
Effects of acute SNP exposure
Signiﬁcant airway inﬂammation was observed for each type of
SNP treatment; however, the level of inﬂammation varied
according to the surface characteristics of the SNP used. The
results of BALF examination revealed statistically signiﬁcant
variation in the differential cell counts performed on the S-SNP
group as compared with the control group, including the total
cell count, macrophage count and neutrophil count. Lympho-
cytes were signiﬁcantly higher in the S-SNP group than in the
other groups. The M-SNPs and P-SNP groups also demon-
strated higher total cell and macrophage counts than did the
control group, but without statistical signiﬁcance. The M-SNP
Figure 2 Experiment scheme. (a) Experiment 1: acute SNP
exposure models. (b) Experiment 2: acute exposure to SNPs with
OVA-induced asthma models. exp, experiment; IN, intranasal
inoculation; IP, intraperitoneal injection; OVA, ovalbumin; SNP,
silica nanoparticle.
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and P-SNP groups induced a smaller increase in cell count than
did the S-SNP group (Figure 3a).
Signiﬁcantly higher AHR was observed in the S-SNP group
than in the control group. The M-SNP and P-SNP groups
also demonstrated higher AHR than did the control
group, but lower than the AHR observed in the S-SNP
group. No statistically signiﬁcant differences were observed
(Figure 3b).
In each of the SNP groups, histologic examination revealed
higher peribronchial and perivascular inﬂammation than that
observed in the control group. The S-SNP group demonstrated
marked increase in bronchial epithelial thickness with abun-
dant inﬂammatory cell inﬁltration. The histologic ﬁndings
between M-SNP and P-SNP groups could not be visually
discriminated (Figure 4).
Higher levels were obtained for the S-SNP group than the
control group for each cytokine measured, including IL-5,
IL-13, IL-1β and INF-γ. The levels of IL-5 and IL-13, which
are known as helper T cell type 2 (Th2) cytokines, were lower
in the P-SNP group than in the S-SNP group; however, none
of the cytokine measurements demonstrated a statistically
signiﬁcant difference (Figure 5).
Effects of acute SNP exposure in the OVA-induced asthma
model
SNPs, inoculated thrice in conjunction with OVA, induced
asthma in the mice. Upon examination of the BALF, the total
cell counts in the S-SNP and M-SNP groups were signiﬁcantly
higher than that in the control group. The number of
macrophages was signiﬁcantly higher in the S-SNP and
M-SNP groups than in all of the other groups—the control
group, OVA-only asthma group and P-SNP group. Eosinophils
were signiﬁcantly elevated in the S-SNP and M-SNP groups
than in the control group. The total number of cells and
eosinophils were higher in the P-SNP group than in the control
group, but lower compared with those of the S-SNP and
M-SNP groups (Figure 6a).
AHR measurements in the OVA asthma group were greater
than in the control group, yet without statistically signiﬁcant
meaning. Overall, no signiﬁcant difference in AHR was
observed among the various SNP groups (Figure 6b).
Signiﬁcantly more cellular inﬁltration in peribronchial and
perivascular tissues was observed in the OVA asthma group, as
well as in the three SNP groups, as compared with the control
group. No statistical difference was observed among the OVA
asthma group and each of the SNP groups (Figure 7).
IL-5 and IL-13 levels were statistically signiﬁcantly greater in
the OVA asthma group and SNP groups than in the control
group. No signiﬁcant statistical difference was noted between
the OVA asthma group and each of the SNP groups. Similarly,
the levels of IL-1β and INF-γ were higher in the OVA asthma
group and SNP groups than in the control group; however, no
statistically signiﬁcant difference was observed. The P-SNP
group demonstrated lower levels of IL-5, IL-13, IL-1β and
INF-γ than the OVA asthma and other SNP groups, except the
control group (Figure 8).
DISCUSSION
This study demonstrated that acute exposure, simulated just
once per day for 3 days, can harm the respiratory system. Acute
SNP exposure, as demonstrated here, can induce signiﬁcant
airway inﬂammation and aggravate allergic airway inﬂamma-
tion in the OVA-induced asthma models.
In this study, short-term exposure to SNPs induced respira-
tory inﬂammation with associated AHR in each of the S-SNP,
M-SNP and P-SNP groups. Both BALF and histologic exam-
ination showed signiﬁcantly higher cell counts in the S-SNP
group than in the control group. Acute exposure to SNPs in
conjunction with OVA (OVA/SNPs asthma model) also
induced severe airway inﬂammation when compared with
those treated with OVA alone. No signiﬁcant difference in
AHR was observed among all the groups, including mice in the
OVA asthma group and OVA/SNPs asthma mice. Both
models showed increased levels of Th1 cytokines (IL-1β and
interferon-γ) and Th2 cytokines (IL-5, and IL-13), without
signiﬁcant statistical difference. Some studies have shown that
Th2 cytokines have a key role in airway toxicity.10,29,30
However, in this study, increased macrophage counts in BALF
samples and increased levels of IL-1β and interferon-γ were
Figure 3 The airway inﬂammation as demonstrated in (a)
bronchoalveolar lavage ﬂuid (BALF) and (b) airway hyper-
responsiveness in acute SNP exposure models. *Po0.05 between
two variables; #Po0.05 compared with others. M-SNP, mesoporous
silica nanoparticle; P-SNP, PEGylated silica nanoparticle; RL,
resistance of lung; S-SNP, spherical silica nanoparticle.
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observed, particularly in the SNP models. It could be assumed
that this airway inﬂammation was induced not only via the Th2
pathway but also via the Th1 pathway.
Th1- and Th2-related immunity maintain a delicate balance.
If one side increases, the other side naturally decreases. Several
Th1 enhancers reduce Th2-related immunity.31 OVA induces
Th2-related immunity, whereas SNPs are hypothesized to
induce Th1-related immunity. Therefore, OVA/SNP groups
will induce a Th2-related response to a lesser extent than that
in only OVA-treated groups. Indeed, the AHR and the IL-5 and
Figure 4 Histological ﬁndings of lungs representing peribronchial and perivascular tissues in the (a) control group, (b) S-SNP group,
(c) M-SNP group and the (d) P-SNP group. M-SNP, mesoporous silica nanoparticle; P-SNP, PEGylated silica nanoparticle; S-SNP, soluble
silica nanoparticle.
Figure 5 Cytokine levels of (a) IL-5, (b) IL-13, (c) IL-1β and (d) IFN-γ in acute SNP exposure models. IFN-γ, interferon-γ; IL-5, interleukin-
5; M-SNP, mesoporous silica nanoparticle; P-SNP, PEGylated silica nanoparticle; S-SNP, spherical silica nanoparticle.
Silica nanoparticles aggravate airway inﬂammation
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IL-13 levels in OVA/SNP groups decreased compared with that
in the OVA group (Figures 6b and 8). SNP, a Th1 immunity
enhancer, may reduce the Th2-related immunity by lowering
AHR and by lowering the levels of IL-5 and IL-13. In contrast,
OVA, a Th2 enhancer, may reduce Th1-related immunity. The
decrease in macrophage counts in BALF in the OVA/SNP
model compared with those in the SNP model is the result of a
protective effect of OVA against Th1-related immunity
(Figures 3a and 6a). However, overall inﬂammation based on
the total cell count in BALF and pathologic ﬁnding revealed
that the OVA/SNP model induced severe inﬂammation.
Although not statistically signiﬁcant, we believe that SNP
slightly reduced Th2-related immunity induced by OVA by
inducing Th1-related immunity. Therefore, overall total
inﬂammation induced by OVA/SNP is similar to or more
severe than that in the OVA- or SNP-treated groups.
We selected a speciﬁc dose of SNPs (200 μg per mouse) for
this study. Previous studies have revealed that there is a dose-
dependent effect of SNP-induced airway inﬂammation.19 Thus,
most current studies use a speciﬁc dose of SNP (12.5–200 μg)
to evaluate its toxicity.32 The number of SNP in ambient air
range from 2× 104 to 2× 105 cm− 3, with mass concentrations
of 450 μgm− 3 near major highways.13 Average breathing
volume per day is approximately 15–25m3. An individual
working near a major highway might therefore inhale any-
where between 750 and 1250 μg of SNP in a day. In mouse
experiments of toxicity to a speciﬁc material, 10- to 1000-fold
of what is considered a toxic dose of the study compound
to be invesigated is typically used. We selected an SNP dose of
~ 400-fold, calculated based on the mass of SNP typically
inhaled relative to body mass (human: 0.02 μg g− 1; mouse (in
this study): 8 μg g− 1). We believe that this SNP dose of 200 μg
per mouse is clinically feasible. Indeed, these experiments
showed signiﬁcantly increased AHR, which is of clinical
importance, inducing clinical signs such as cough and dyspnea
under the stimulation of less irritable materials.
Many studies have demonstrated that the toxicity of SNPs
depends on several factors, including size, surface area, electric
charge and function.33,34 Some studies have revealed correlation
between the surface pattern of SNPs and the level of toxicity;
2,35 however, results vary according to experimental setting and
designs. In this study, the toxicity of acute SNP exposure varied
owing to the surface pattern of the SNP. In acute SNP exposure
models, the P-SNP and M-SNP groups induced less airway
inﬂammation than the S-SNP group, without statistical
signiﬁcance. Among OVA/SNP asthma mice, those in the
P-SNP group induced lesser signs of airway inﬂammation than
those in the S-SNP and M-SNP groups, and the difference was
statistically signiﬁcant. The contact area is a critical factor for
inducing toxicity during the interaction between SNPs and
tissues. The contact and surface area of M-SNPs is largest
among the three kinds of SNPs (M-SNPs, 70.6m2 g− 1; S-SNPs,
12.7m2 g− 1). Smaller surface area has lesser opportunity to
interact with tissue to induce inﬂammation. Therefore, the
larger surface area of M-SNPs could induce the most severe
inﬂammation compared with the other SNPs in this study. In
P-SNPs, the surfaces of S-SNPs are functionalized with the
biocompatible PEG ligands. Therefore, P-SNPs exhibited the
lowest toxicity among three different types of SNPs.
In summary, the toxicity of SNPs was lower in the P-SNP
group than in the S-SNP or M-SNP group. P-SNPs did induce
airway inﬂammation but lesser than did S-SNPs and M-SNPs
induce. P-SNPs induce lesser inﬂammation on the airway, with
reduced inﬂammation in OVA/SNPs asthma models. P-SNPs
may be more suitable for use in various medical/pharmaceutical
ﬁelds, including drug delivery systems, diagnostic carriers and
other medical applications. The harmful effects associated with
SNPs should be carefully considered before implementation,
particularly when exposure of the airway system is possible.
Although various studies have evaluated the toxicity of SNPs,
this study cannot be compared with the previous work owing
to signiﬁcant differences in its experimental design. This study
focused on examining respiratory system response after short-
term exposure to SNPs, with or without OVA sensitization, as
well as the different effects of SNPs according to their surface
patterns. These results contribute to the existing knowledge
base for SNP usage in scientiﬁc and industrial ﬁelds.
Figure 6 Airway inﬂammation as determined by analysis of (a)
bronchoalveolar lavage ﬂuid (BALF) and (b) airway hyper-
responsiveness in OVA/SNPs asthma models. *Po0.05 between
two variables; #Po0.05 compared with others. M-SNP, mesoporous
silica nanoparticle; OVA, ovalbumin; P-SNP, PEGylated silica
nanoparticle; RL, Resistance of lung; S-SNP, spherical silica
nanoparticle.
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However, the present study did not completely examine the
effect of SNPs in conjunction with OVA in the OVA/SNPs
asthma models to determine its use as an adjuvant. The OVA-
only group demonstrated lower total cell counts and macro-
phage counts in BALF than the S-SNP and M-SNP groups. As
S-SNPs and M-SNPs can induce airway inﬂammation on their
own, it could not be determined whether the increased effects
observed in the OVA/SNP asthma models are due to actions of
SNPs alone, or because of an adjuvant effect with OVA. To
evaluate more accurate pro-inﬂammatory effects and adjuvant
effects of OVA/SNP models, further study is required. More-
over, the present study revealed that Th2 and Th1 cytokines are
Figure 7 Histological ﬁndings in peribronchial and perivascular tissues of the (a) control group, (b) OVA-only group, (c) S-SNP group,
(d) M-SNP group and (e) P-SNP group. M-SNP, mesoporous silica nanoparticle; P-SNP, PEGylated silica nanoparticle; S-SNP, spherical
silica nanoparticle.
Figure 8 Cytokine levels including (a) IL-5, (b) IL-13, (c) IL-1β and (d) IFN-γ in OVA/SNPs asthma models. #Po0.05 compared with
others. IFN-γ, interferon-γ; IL-5, interleukin-5; M-SNP, mesoporous silica nanoparticle; P-SNP, PEGylated silica nanoparticle; S-SNP,
spherical silica nanoparticle.
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associated with toxic effects of SNPs; however, the mechanisms
by which SNPs induce inﬂammation on the respiratory system
have not yet been fully evaluated. A more accurate evaluation
of this mechanism, as well as further cytokine and gene studies,
is required.
In conclusion, this study demonstrated the toxic effects
of acute SNP exposure. Acute SNP exposure can induce
signiﬁcant airway inﬂammation, and further aggravate airway
inﬂammation, as demonstrated in the OVA asthma model. In
terms of surface characteristics, P-SNPs appear to be safer for
clinical use than S-SNPs or M-SNPs.
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